Search

Sponsor opportunities

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies with the practical tools to translate emerging data into the best therapy for…

Read more

Emeritus membership

If you're a scientific researcher, physician, or healthcare-affiliated professional who's now retired or is close to retirement, you can join EHA at a reduced rate.

Read more

Mission

The European Hematology Association (EHA) promotes excellence in patient care, research, and education in hematology.

Read more

BENIGN HEMATOLOGY in 2023 and beyond

The term "benign hematology" has traditionally been used to refer to non-malignant blood disorders. However, over the past few years, questions have been raised as to the appropriate nomenclature for this category of diseases.

Read more

The February 2018 - Volume 2 - Issue 1 of HemaSphere is now available online

The February 2018 - Volume 2 - Issue 1 of HemaSphere is now available online. HemaSphere is an open access journal, powered by the European Hematology Association and dedicated to support hematology patient care, research and education worldwide.

Read more

Full membership

Our most popular type of membership is designed for established scientific researchers and physicians.

Read more

Social Media Learning

EHA presents our own microlearning in 4 formats, covering diagnosis, pathology, clinical schemas, and clinical cases within topics in the European Hematology Curriculum.

Read more

Hospital pharmacists and regulators lead the way on shortages

EHA welcomes initiatives but calls for more focus on causes

Medicine shortages have a negative impact on the quality and cost of treatments and on patient access to the best possible care.

Read more

From bedside to Brussels: hematology at the forefront of EU health policy

Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.

Read more